- Home
- BAFN vs ANTX Comparison
BAFN vs ANTX Comparison
Compare BAFN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAFN | ANTX |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 172.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BAFN | ANTX |
|---|---|---|
| Price | $6.94 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 102.6K | ★ 295.2K |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $1.00 |
| 52 Week High | $9.70 | $7.19 |
Technical Indicators
Market Signals| Indicator | BAFN | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 29.98 |
| Support Level | $5.98 | $2.87 |
| Resistance Level | $6.96 | $5.15 |
| Average True Range (ATR) | 0.62 | 0.33 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 74.01 | 14.64 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.